Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

The EMPOWER observational study of Vormatrigine in Epilepsy.

Next Previous
Trial Profile

The EMPOWER observational study of Vormatrigine in Epilepsy.

Status: Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 04 Apr 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Vormatrigine (Primary)
  • Indications Epilepsy
  • Focus Therapeutic Use
  • Acronyms EMPOWER

Most Recent Events

  • 24 Mar 2025 According to a Praxis Precision Medicines media release, data from this study will be presented in a Poster presentation (P9-012) on Monday, April 7, 8:00 AM - 9:00 AM PT at the American Academy of Neurology (AAN) 2025 Annual Meeting taking place from April 5 to 9, 2025 in San Diego, California.
  • 05 Mar 2025 New trial record
  • 28 Feb 2025 According to a Praxis Precision Medicines media release, Early results were shared during the Praxis scientific exhibit at the December 2024 American Epilepsy Society (AES) Annual Meeting, demonstrating significant disease burden compounded by persistent, uncontrolled, often untracked seizures alongside profound psychosocial impact.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top